Guidelines International Network | Guidelines International Network (GIN)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma

MeSH Terms: Musculoskeletal System (A02);Skeleton (A02.835);Bone and Bones (A02.835.232);Bones of Lower Extremity (A02.835.232.043);Leg Bones (A02.835.232.043.650);Femur (A02.835.232.043.650.247);Neoplasms (C04);Neoplasms by Histologic Type (C04.557);Neoplasms, Glandular and Epithelial (C04.557.470);Carcinoma (C04.557.470.200)
Guideline Contact: guidelines@asco.org
Publication Date: 01-Oct-20
Date of Last Evidence Search: 01-Jul-19
Publication Scope: management; treatment
Countries of Application: United States
Guideline Publication Status: Published
Languages: English
Authors: ASCO (US); ASTRO (US)
Publication Year: 2020

MeSH Terms: Randomized Controlled Trial (V03.200.700); Randomized Controlled Trials as Topic (E05.318.760.535.365.500); Melanoma (C04.557.465.625.650.510); Radiotherapy (E02.815)
Guideline Contact: Cindy Walker-Dilks (pebconc@mcmaster.ca)
Publication Scope: treatment
Countries of Application: Canada
Guideline Publication Status: Published
Languages: English
Authors: McMaster University (CA)
Publication Year: 2016

MeSH Terms: Pituitary Diseases (C19.700); Hormone Replacement Therapy (E02.319.452); Pediatrics (G02.403.776.610)
Publication Scope: management
Countries of Application: Malaysia
Guideline Publication Status: Published
Languages: English
Authors: HTA DoH (MY)
Publication Year: 2010

MeSH Terms: Levoleucovorin (D03.438.733.631.400.800.350.450.500); Fluorouracil (D03.383.742.698.875.404); Colorectal Neoplasms (C04.588.274.476.411.307); Leucovorin (D03.438.733.631.400.800.350.450)
Guideline Contact: Cindy Walker-Dilks (pebconc@mcmaster.ca)
Publication Scope: treatment
Countries of Application: Canada
Guideline Publication Status: Published
Languages: English
Authors: McMaster University (CA)
Publication Year: 2016

MeSH Terms: Cardiovascular Diseases; Decision Making, Computer-Assisted; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary prevention
Guideline Contact: Kristophe De Meester
Publication Date: 23/01/2020
Publication Scope: Provide locally-adaptable, clear, science-informed, clinical practice recommendations on the management of patients with LMD in terms of revascularization modality: CABG or PCI.
Countries of Application: Belgium
Guideline Publication Status: Published
Languages: Dutch; English; French
Authors: KCE (BE)
Publication Year: 2020

MeSH Terms: Meta-Analysis (V03.600); Randomized Controlled Trial (V03.200.700); Random Allocation (E05.318.780.700); Lung Neoplasms (C04.588.894.797.520)
Guideline Contact: Cindy Walker-Dilks (pebconc@mcmaster.ca)
Publication Scope: treatment
Countries of Application: Canada
Guideline Publication Status: Published
Languages: English
Authors: McMaster University (CA)
Publication Year: 2015

MeSH Terms: Meta-Analysis as Topic (E05.581.500.501); Meta-Analysis (V03.600); Randomized Controlled Trial (V03.200.700); Kidney Neoplasms (C04.588.945.947.535); Carcinoma; Renal Cell (C04.557.470.200.025.390); Angiogenesis Inhibitors (D27.505.696.377.077.099); Antineoplastic Agents (D27.505.954.248)
Guideline Contact: Cindy Walker-Dilks (pebconc@mcmaster.ca)
Publication Scope: treatment
Countries of Application: Canada
Guideline Publication Status: Published
Languages: English
Authors: McMaster University (CA)
Publication Year: 2017